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DEAR EDITOR, We read with interest the informative article by Kouamé et al. describing mortality in 
HIV/Hepatitis B virus (HBV)-coinfected patients on antiretroviral therapy (ART) in West Africa (1). In 
line with studies from high-income countries, the results from the Temprano trial show that active 
HBV infection increases mortality among HIV-infected individuals (2). However, clinical trial data 
cannot be generalized to other clinical settings in sub-Saharan Africa (SSA), where resources for 
patient monitoring and management are limited and patient who initiate ART have often present 
with advanced stages of disease and comorbidities. Real-life data on the impact of HBV 
determinants on mortality from primary HIV care settings in SSA are scarce.  
Since January 2013, we recruited consecutive HIV-infected patients at time of ART initiation into a 
prospective cohort in Lusaka, Zambia, and Ancuabe, a rural area in Mozambique, within the IeDEA 
collaboration (3). All patients were tested for the presence of chronic HBV infection, defined as a 
positive HBsAg rapid test (Determine®, Alere, Yavne, Israel), and HBV viral load (VL) was measured in 
HIV/HBV-coinfected individuals using quantitative real-time polymerase chain reaction (Roche, 
Indianapolis, USA) from plasma or dried blood spots (4). The systematic tracing of patients lost to 
follow-up (LTFU, ie. >3 months without a clinical visit) during the first year of ART was performed by 
phone calls or home visits. We used multivariable Cox proportional hazard methods to compare one-
year mortality between HBV-infected and uninfected patients.  
Fourteen percent (276/1,948) of the study participants were HBsAg-positive, of whom 137 (49.6%) 
had an HBV VL above 2000 IU/ml. Median age was 32 years (interquartile range [IQR] 26-40 years), 
median CD4 count 252 cells/µl (IQR 130-369), 38% had WHO stage 3 or 4, and 36% were female. 
There were no significant differences in CD4 cell counts, body mass index, age, and proportions with 
advanced HIV disease between groups. HBsAg-positive individuals were more likely to be male 
(p<0.001). After one year of ART, 129 (6.6%) patients had died, 113 (5.8%) were LTFU and 63 (3.2%) 
transferred or withdrew from the study. One-year mortality was 6.5% (95% confidence interval 5.4-
7.8%) in HIV-infected patients, 8.7% (4.9-15.2%) in HIV/HBV-coinfected ones with HBV VL <2000 
IU/ml, and 8.2% (95% CI 4.4-15.2%) in HIV/HBV-coinfected patients with HBV VL >2000 IU/ml. In 
multivariable analyses, HBsAg-positivity was not associated with mortality (Table).  
As opposed to Kouamé et al., we did not find a significant difference in mortality between HIV-
infected individuals with active HBV infection and HBV-uninfected ones in southern Africa. We 
provide robust mortality estimates from primary care clinical settings in SSA, as we limited the risk of 
under-estimating death rates by systematically tracing patients LTFU (5). Although the burden of 
liver-related mortality due to HBV infection is high in SSA (6), mortality of patients initiating ART 
outside of clinical trials remains driven by HIV-associated causes. As low-income countries are 
starting to implement the “treat all” strategy for HIV infection, the impact of HBV infection on 
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clinical outcomes might become more evident. Therefore, long-term data from cohorts with 
intensive retention strategies will be crucial to inform monitoring of HIV/HBV-coinfected individuals 
in the near future. 
 
Table. Risk factors for 1-year mortality, according to multivariable Cox proportional hazard 
regression analyses  
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 Deaths (%) HR (95% CI) p-value aHR (95% CI) p-value 
HBsAg (%)      
    negative 102/1673 (6.1) Ref.  Ref.  
    Positive 27/276 (9.8) 1.61 (1.05-2.45) 0.03 1.21 (0.74- 1.98) 0.45 
WHO stage (%)      
    1 or 2  50/1203 (4.2) Ref.  Ref.  
    3 or 4 79/732 (10.8) 2.69 (1.88-3.83) <0.001 1.42 (0.93- 2.17) 0.10 
CD4 cell count (%)      
    ≥200 cells/µl 41/973 (4.2) Ref.  Ref.  
    <200 cells/µl 71/640 (11.1)  2.76 (1.88-4.05) <0.001 2.02 (1.33-3.07) 0.001 
BMI (%)      
    ≥18.5 kg/m2 48/1275 (3.8) Ref.  Ref.  
    <18.5 kg/m2 67/519 (12.9) 3.60 (2.49-5.22) <0.001 2.66 (1.76- 4.02) <0.001 
Sex (%)      
    Female 52/1240 (4.2) Ref.  Ref.  
    Male  77/708 (10.9) 2.63 (1.85-3.74) <0.001 1.72 (1.13- 2.62) 0.01 
Age (%)      
    <30 years 43/772 (5.6) Ref.  Ref.   
    ≥30 years  86/1176 (7.3) 1.29 (0.89-1.85) 0.18 0.97 (0.63- 1.50) 0.89 
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